WInnovations host Dr. Kyle Richards welcomes Corinna Hughes, DNP, PNP-L, an instructor and urology nurse practitioner at Mayo Clinic in Rochester, and Ashli Ellison, NP, a nurse practitioner in the Urology Department at the University of Wisconsin. The three explore how advanced practice providers (APPs) are transforming urologic care and expanding access for patients, as our guests share their journeys into urology, break down what it means to be an APP, and outline the education, training, and fellowship pathways that prepare them for this specialized field.

They also discuss the scope of practice: what APPs can do, how independence and supervision vary by state, and the growing demand for these roles across healthcare. Finally, our guests address common patient perceptions, opportunities to learn procedures, and how APPs are helping optimize care delivery in urology.

In part two of a two-part interview, WInnovations host Dr. Kyle Richards is joined by Dr. Elizabeth Koehne, assistant professor and urologic oncologist at the University of Wisconsin Department of Urology, and Dr. Sam Chang, professor and chief of urologic oncology at Vanderbilt University. The conversation continues with a deeper dive into emerging treatments for non–muscle invasive bladder cancer, with a particular focus on the growing role of biomarkers in guiding care and identifying the right therapy for the right patient. The discussion also further explores evolving strategies for patients with BCG-unresponsive disease, including promising therapeutic options amid the ongoing BCG shortage.

In part one of a two-part interview, WInnovations host Dr. Kyle Richards is joined by Dr. Elizabeth Koehne, assistant professor and urologic oncologist at the University of Wisconsin Department of Urology, and Dr. Sam Chang, professor and chief of urologic oncology at Vanderbilt University, for a forward-looking discussion on emerging treatments for non-muscle invasive bladder cancer. Together, they break down key advances in care – from updates to standard surgical approaches and promising alternatives to navigating the ongoing BCG shortage and exploring new options for patients with BCG-unresponsive disease.